Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Still expecting 'stuff' soon. RFK Jr is making a lot of headway when it comes to small bios having more influence in the drug space.
Just reading the rule itself, and the SEC doesn't really do business over "simple phone calls." Notification would have happened after 9 months (February) giving 30 days (March) to update or withdraw, and the fact the SEC posted a letter would mean they didn't get a response which should be written one way or another.
It isn't unrecoverable, considering the registration statement has to be revised again anyway, way out of date after a year. The board authorization for the accompanying reverse split ends in October.
The simple phone call to SEC can correct it and it was corrected
Not correct?
Here's the rule:
https://www.customsmobile.com/regulations/title17_chapterII_part230_subjgrp46_section230.479
It's been more than 9 months with no revisions. Reading the rule, what may have been incorrect was the SEC posting their notification.
This SEC letter has been taken down from the SEC's website as it was not correct.
The SEC comments were removed so we still on.
Yeah 3 was making promises like .20 before funding. Some Dubai bullsheet what a scam artist 3 is
Steve / Student, care to explain?
3, how does this fit into your perspective?
Nope....
Registration statement abandoned:
https://www.sec.gov/Archives/edgar/data/1400271/999999999725002314/filename1.pdf
That was the one they filed to get funding and uplist.
Are we imminent yet?
8 weeks left in q2. lol
Richard Garr claimed in an interview this year that trials should be expected in the second quarter 2025. Does anyone believe that will hold up?
I scammed you? Lol. Look at my posts the past 3 years. This fell from .20 to .01 and I was a hater all of the way down. I was the biggest critic there was here. I only VERY recently became bullish on CUBT. And for good reason.
I am still VERY positive here. And again, if you saw my posts from 3 years ago you know that is a big change.
Just a matter of time (not long imo) before this starts to roll.
This is toast. 3f scammed all of us including you
It is still quiet period For the last 3 years?
When I'm able to, I will!!
Provocation lookin for an update. Not a roll call. Next time you message have something to offer.
I don't think he's moved on or given up!!
Student has moved on. I Don’t think he gives a sheet any more. Gave up like the rest of us
CUBT: We wait. What's next here? 3F knows? Student knows? Who knows?
Paul Knows I bet and RG knows.
I know that the RS ratio announcement after Paul gave the power to RG, KILLED this stock and now look.
Educated and articulate doesn't equate to success in OTC.
Proof is in the PPS here right now and the OS is going up.
JMHO
You're not missing anything. We are missing everything. Nobody knows what's going to happen with this company but I believe they still exist which is a kind of good sign. But if the programs they have are so great. Why is nobody want to invest even $1 million for it? That's the good question
Tell me if I'm missing something with respect to the conversion price of the different types of Preferred stock. I don't see anything stipulating that the conversion prices for the preferred shares are changed if there is a reverse split of the common stock.
Oh my f?king god. Are you a joker or what
That's a horrible read. What a bunch of A holes. A lot of dilution on this and more I. The works.
Nobody is investing here it's a share printing press.
You and 3f so full of sheet
End of the year disclosure released. Looks like there is much more people investing in this in this company
It's a quiet. You're not going to get any response from anybody. It's a shame what's going on with this company
Open Letter to Curative Biotech ($CUBT) Management
To the leadership of Curative Biotech,
Shareholders have had enough of the silence, the delays, and the complete lack of progress.
CUBT has promising assets. But none of it matters if management refuses to execute. No funding. No clinical trials. No clear updates. And now you’re floating a reverse split? That’s a slap in the face to loyal investors who’ve stuck around through years of nothing.
Let’s be clear:
• You’ve failed to secure funding.
• You’ve failed to initiate trials.
• You’ve failed to communicate with shareholders.
• And now you’re trying to mask the failure with a reverse split?
Unacceptable.
Here’s what needs to happen NOW:
1. Get the funding secured. If current leadership can’t do it, bring in someone who can.
2. Start the clinical trials. The pipeline means nothing without action.
3. CANCEL the reverse split. It’s not a solution—it’s an admission of failure.
Shareholder value has been destroyed long enough. If management has any integrity left, it’s time to act. Not next quarter. Not “soon.” Now.
We’re not going to sit quietly while you run this company into the ground. Either do your job—or step aside and let someone else lead who actually will.
• A glowingly impatient Shareholder
Nice move up today folks. What will the RS ratio be?
https://www.barchart.com/stocks/quotes/CUBT/opinion
there's hope 🤞
Hmmm. You said financing end of March. Hmmm. You bought billions of shares
Hmmm. Your richard garr. Yes!!! That's it
I think you are going to see a lot of money flow into the OTC market throughout the spring/summer until the tariff situation is resolved. The OTC has been the one market that has not seen any action since 2021 or so. Every other market from real estate, to the NASDAQ and the DOW, to crypto....has had huge runs the past 4 years. Not the OTC.
Believe it or not it might be a safe investment right now. Especially the small bio techs as RFK Jr is very small bio friendly and the financial lending markets are opening up.
I have been buying recently. I have a lot of shares but my average went down to 0.028
Dow down 2000. I’m up 20% today with $CUBT.
Curative is my safe investment. While normal investors are crying in their soup, I am laughing all the way to the bank. Does it get any better than this?
I mean, yeah it would be cool if I could actually sell my shares one day, but let’s not get bogged down in details.
So you bought 10,000 to prove you a point for me. It was the same story. Nothing about financing
CUBT Interesting interview. This is a high up govt official in the RFK Jr.'s Health Administration, and he talks about how Big pharma has been stifling innovation in medicine and how RFK, as I talked about previously, is going to enable small biotechs (like CUBT) to be able to get the funding and the clearance to enact their research and cures. Things that previous Administrations didn't allow.
Only a fool believes you
I have no insider info. Just basing my opinion on what I hear from people who work in the financial markets and how it will help companies like CUBT.
Tomorrow is the day April 1 fool's Day the financing is going to come finally
noted. i haven't added more shares but he did get my hopes up for the bag that i've had for 2 years. LOL.
Wow your really drinking his kool aid.
He's been wrong 100% of the time. He was certain money was flowing here last week and this week. He stated do 2-4 weeks ago
That's just one of countless examples. He never said he had inside info rather he knew a guy. Just saying be aware he's not really someone to take advice on this stock.
I'm not saying he has any ill will or trying to screw board members and observers. I have no evidence of that. But insider info or other investment advice I'd place my bets elsewhere
Glta
are you hinging your hopes and dreams solely on this administration's stance on deregulation and rare disease/advanced therapies? i was really hoping you had insider information...
It's guaranteed to be an RS 1:400. It's in the filings and even student confirmed it. There's always risk it could be higher up to 1:10000. But let's hope that's not the case
They won't RS if there's no financing and uplist. So the question I still have is. Will they RS before or after financing. If after you could buy the falling knife since there's no restrictions on these new investors. This is what I've read here and been told. Be well my brother
If the CEO can confirm to me that he won't RS, I'm Loading a lot here.
If not, I will wait for the RS and dilution and see what the CEO does and how much he shits on us.
I got my umbrella
The CEO can fix this. Get it going CEO and fix your BS of a stupid RS ratio, prove to the loyal shareholders that you won't dilute, prove you are true to the loyal shareholders, and respect the loyal retail that had and can make this stock prosperous. You are very articulate in the interviews; Paul is my favorite.
Paul was always extremely shareholder friendly.
Prove to us you are shareholder friendly and won't dilute on our heads here.
I will add over $1M++ cash if you can prove to me that you are truly shareholder friendly like Paul was initially.
Paul was the main reason I invested here. He was shareholder friendly.
A non-dilution CEO.
A CEO that cared about his true loyal shareholders.
RG came in and said fuck the retail shareholders, He put in a bs massive reverse split ratio and he wants to get the institutional shareholders which has proven to dis him. He fucked us retail shareholders. He said fk the retail shareholders that actually helped the company propel up. RG I love you and see you are very articulate, but you fk'd us on the filing for a potential massive RS ratio. FIX IT. Correct it. You can.
Richard needs to get with Paul and needs to get in line and respect the loyal retail shareholders.
Get in line and respect the loyal investors that have propelled this company PPS UP.
Agree your credibility is toast here bro. The overhead RS is the biggest risk here by RG. Are you paid here by RG to promote here that the RS is not a threat here?
Why did you change your tune here? Asking for a friend LOL.
Agree and I said that MANY times back then.
Followers
|
301
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
44853
|
Created
|
03/17/09
|
Type
|
Free
|
Moderators Eagle1 Student of the Game trader59 |
OTC: CUBT http://CurativeBiotech.com INVESTOR PRESENTATION https://curativebiotech.com/news-and-media/presentations Curative Biotechnology, a development-stage biomedical company, focuses on novel treatments for rare diseases. The company focuses on therapies with potentially accelerated development paths as a result of the disease, the nature of the therapeutic itself, or the stage of clinical development. Its pipeline candidates include CURB906, an antibody-drug conjugate for targeting CD56 positive brain tumors; and IMT504, a novel immune therapy to treat rabies. The company has an agreement with Mid-Atlantic BioTherapeutics, Inc. to develop an adjuvant for the COVID-19 vaccines which enhance antibody response. Current Drug Pipeline https://curativebiotech.com/pipelineTreatments for six (6) Ocular conditions, one (1) Oncology, one (1) Infectious disease and one (1) vaccine adjunct candidate* Metformin eyedrops for treatment of Acute Macular Degeneration (AMD) AMD is a visually threatening condition, most often found in patients over age 60. Early and Intermediate AMD are characterized by enlarged drusen behind the eye’s retina. Close to 10% of the world’s population is over 60, increasing the prevalence of age-related macular degeneration. Dry AMD accounts for 80-90% of AMD cases, while wet AMD is 10-20% of cases. Currently there are no approved drug treatments for Dry AMD or Geographic Atrophy (late stage dry AMD). Wet AMD is caused by blood vessels that leak in the retina. These abnormal blood vessels may leak fluids or blood into the back of the eye. Curative Biotech will reformulate metformin to treat intermediate dry AMD and Geographic Atrophy for the first indications. Development to be led by the lead inventor on the NEI Patents, Dr. Kapil Bharti. Curative is in negotiations with NEI to conduct the first clinical trial. This product may be eligible for 505(b)(2) treatment as a reformulation of an already approved drug. The global age-related macular degeneration (AMD) market is expected to attain a value of $8.9 billion by 2022 Stargardt DiseaseStargardt disease is a type of inherited age-related macular degeneration that causes vision loss in children or young adults.The retina contains light-sensing cells called photoreceptors, which include rods and cones. Rods are in the outer retina and help people when lighting is dim and dark. Cones are in the macula and help people see intricate visual detail and color. Both cones and rods negatively affected in Stargardt disease, cones are more strongly impacted in people who have Stargardt disease. The Global Stargardt Disease Therapeutics Market is estimated to be valued at US$ 213.5 million in 2023 and is expected to exhibit a CAGR of 31.7% during the forecast period (2023 - 2028). Retinitis PigmentosaRetinitis pigmentosa (RP) is a genetic disorder which leads to a gradual loss of sight, causing a deterioration of night vision and peripheral vision. People with RP experience a gradual decline in their vision, because photoreceptors degenerate. Retinitis pigmentosa, is a condition where patients typically loses ability to see at night in young years, side vision in middle age, and focal vision in later in his/her life due to relentless loss of cone photoreceptor cells. Retinitis Pigmentosa (RP), an acquired retinal condition that causes retinal depletion, is an uncommon illness. Its underlying manifestations are decreased night vision along with loss of fringe vision. It slowly causes visual impairment. There is no conclusive remedy for retinitis pigmentosa. Hence medical institutions and various research and development centers are researching to develop a full proof cure for this disease which is boosting the growth of global retinitis pigmentosa market. ChoroideremiaChoroideremia is a hereditary degeneration of the retina in males that causes a gradual loss of vision. It starts in early childhood with night-blindness, then follows with peripheral vision loss and eventually progresses to the loss of central vision. The lack of a functional protein in the retina causes cell death that is followed by the gradual deterioration of the retinal pigment epithelium, photoreceptors, and the choroid. Choroideremia results in progressive loss of vision and is more prominent in males. The first symptom of choroideremia is usually night blindness that occurs at an early stage. Global Choroideremia Treatment market is expected to account for $4.3 Billion by 2028 Late Onset Retinal DegenerationLate-onset retinal degeneration occurs in adulthood and is an inherited retinal dystrophy. It leads to central vision loss. https://www.sciencedaily.com/releases/2021/12/211209133927.htm Diabetic RetinopathyDiabetic retinopathy is the leading cause of blindness in adults. It is a complication of diabetes that causes damage to the blood vessels of the retina. At first, diabetic retinopathy may cause no symptoms or only mild vision problems. Eventually, it can cause blindness. The global diabetic retinopathy market reached a value of US$ 7.64 Billion in 2020. and is expected to register a CAGR of 7.6% over the forecast period. Market growth can be primarily attributed to increased funding by regulatory bodies for researching ocular disorders. REFERENCE LINK: https://curativebiotech.com/pipeline |
From 1990 to 2017, worked at National Cancer Insitute of the NIH. Since 2017 Director of Center for Antibody Therapeutics at University of Pittsburgh. Dr. Dimitrov’s major long-term goal is the development of clinically useful therapeutics and vaccines based on human monoclonal antibodies in different formats including engineered antibody domains, chimeric antigen receptors, bispecific antibodies and antibody drug conjugates. He has authored or coauthored more than 370 articles, several books, and is the inventor or coinventor of more than 100 inventions, patent applications or patents. Dr. Dimitrov is the lead inventor on the Antibody Drug Conjugate patent exclusively licensed to Curative Biotech from the National Cancer Institute to treat glioblastoma.
Currently President of Sohn Health Strategies and Adjunct Professor at the University of California, San Francisco.
Dr. Sohn has deep biopharmaceutical industry knowledge with over thirty (30) years of U.S. and global experience with expertise in the development and introduction of new medicines for patients and diseases with significant unmet needs. Her skill sets include strategic product development, business development and the introduction of new vaccines, pharmaceutical products and consumer healthcare brands.
Dr. Sohn started the U.S. Vaccine Business for SmithKline Beecham and led the launch of its first vaccine in the U.S. and helped shape their global vaccine portfolio pipeline as a member of the International Vaccine Steering Committee. Subsequently, she led the US commercialization of the company’s largest CNS product. Dr. Sohn later became senior vice president, Worldwide Business Development and a member of the global executive committee at GlaxoSmithKline Consumer Healthcare where she led U.S. and global transactions, including the $1.3 billion acquisition and integration of Block Drug and the $566 million acquisition of CNS, Inc.
Boca Raton, FL, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) ("Curative Biotech" or the "Company"), a development-stage biomedical company focused on novel treatments for rare diseases and conditions, announced today that it has successfully completed its Investigational New Drug (IND) enabling Tolerance and Toxicology Study of Metformin HCL Solution by Topical Instillation (eye drops) in Rabbits.
Paul Michaels, Chairman and President of Curative Biotechnology, said, "We are pleased to announce the successful completion of these important studies, outlined in our Pre IND meeting with the FDA. We are now able to move on to preparing the Company's first IND application to move our Metformin reformulation into a clinical trial to treat Intermediate Dry Age-Related Macular Degeneration (AMD) and Geographical Atrophy (GA) resulting from AMD."
Michaels continued, "Both Dry AMD and GA are currently unmet medical needs with no FDA approved efficacious treatment options. As previously announced, we will be conducting the first in human study under a CRADA (Cooperative Research and Development Agreement) with the National Eye Institute of the National Institutes of Health, in Bethesda Maryland."
About Macular Degeneration (AMD)
Macular Degeneration is a common eye disorder among people over 50 causing blurred or reduced central vision due from the deterioration of the inner layers of the macula. The macula is the part of the retina that gives the eye clear vision in the direct line of sight. Dry AMD accounts for 80-90% of all age-related macular degeneration (AMD cases), while wet AMD represents 10-20% of patient cases. Currently there are no approved drug treatments for Dry AMD or Geographic Atrophy (late-stage dry AMD).
About Curative Biotechnology, Inc. http://curativebiotech.com
Curative Biotechnology, Inc. (Curative Biotech) is a development stage biomedical company focused on novel therapies for rare diseases. The Company is focused on identifying, acquiring and developing disease modifying therapeutic drug candidates with a concentration on rare disease indications. Curative Biotech has ongoing programs in three different therapeutic areas: infectious disease, neuro oncology and degenerative eye disease. The Company's pipeline includes IMT504, CURB906 and Metformin Reformulation. IMT504 is a novel immune therapy to treat rabies and an adjuvant for vaccines. CURB906 is a fully humanized CD56 monoclonal antibody carrying a cytotoxic drug conjugate directly to the tumor cancer site to kill the tumor by inhibiting tumor growth and migration of the tumor. Metformin Reformulation is targeting the treatment of intermediate and late-stage Age-Related Macular Degeneration (AMD) disease.
Contact:
Steve Chizzikhttps://www.wsj.com/articles/curative-biotechnology-announces-completion-of-ind-enabling-reformulated-metformin-hcl-eye-drop-study-01672923305
Connectyx (now Curative Botechnology) Announces Grant of Exclusive Worldwide License from National Institutes of Health for Repurposing Metformin to Treat Degenerative Eye Disease
Boca Raton, FL, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Connectyx Technologies Holdings Group, Inc. (OTC: CTYX) (“Connectyx” or the “Company”), a development-stage biomedical company focusing on novel treatments for rare diseases today announced it has entered into an Exclusive Patent License Agreement to practice inventions contained within the patent applications listed below with the National Eye Institute (NEI), of the National Institutes of Health (NIH), including the repurposed use of Metformin to treat Retinal Degeneration (RD).
The license patent rights include U.S. provisional patent application No. 62/899,899 and entitled, “Druggable Targets to Treat Retinal Degeneration” filed September 13, 2019 (E-227-2017-US-01); International Patent Application No.: PCT/US2020/050540 and entitled, “Druggable Targets to Treat Retinal Degeneration” filed September 11, 2020 (E-227-2017-PCT-O2); and U.S. and foreign patent applications claiming priority to the applications. The territory for the exclusive license is worldwide.
The degeneration of the Retinal Pigment Epithelium (RPE) is associated with various types of RD such as Stargardt disease, retinitis pigmentosa, choroideremia, late-onset retinal degeneration (L-ORD), and age-related macular degeneration (AMD). In the United States, 11 million people are affected by some form of AMD.
Research has shown that Metformin, an FDA-approved drug that has been widely used for the treatment of diabetes in the United States since 1995, can activate AMP-activated protein kinase, can reduce vascular endothelial growth factor (VEGF) secretion, and can correct baseline calcium levels in patient RPE cells. The new treatment indications will require reformulating the drug into an eye drop, injectable or other topical delivery method to be able to deliver sufficient drug to the RPE layer to have a therapeutic effect. This reformulated drug should be eligible for a 505(b)(2) accelerated development path. While the field of use covers treating any degenerative eye disease, the Company is targeting Stargardt, a currently untreatable orphan disease that causes vision loss in children, as the first indication for this therapeutic product.
Paul Michaels, Chairman and President of Connectyx, said, “We are pleased to expand our product portfolio with the addition of reformulated and repurposed Metformin, which is the fifth most prescribed drug in the United States. This very promising product adds a second in licensed product from the NIH to our development portfolio. As stated above, we believe our Metformin reformulation may show efficacy in treating a wide range of RD diseases that cause vision loss. We are focused on developing disease modifying therapeutics to meet the unmet needs of patients. The Company anticipates being prepared for human testing of this reformulation by third quarter of 2022.”
About Age-Related Macular Degeneration, Stargardt Disease, Retinitis Pigmentosa and Choroideremia
AMD is the leading cause of vision loss in people ages 60+. It destroys a patient’s sharp, central vision. Stargardt disease is a type of AMD that causes vision loss in children or young adults. Retinitis pigmentosa is a genetic disorder which leads to a gradual loss of sight, causing a deterioration of night vision and peripheral vision. Choroideremia is a hereditary retinal degeneration that causes a gradual loss of vision. It starts in early childhood with night blindness, then follows with peripheral vision loss and eventually progresses to the loss of central vision. Diabetic retinopathy is the leading cause of blindness in adults. Diabetes harms blood vessels inside the eye by weakening them so they leak fluid into the retina, which can damage areas of the retina, causing blurry, distorted vision.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |